Document is current
Any future updates will be listed below
-
Authors
Borot, Florence https://orcid.org/0009-0001-5184-8381
Humbert, Olivier https://orcid.org/0009-0003-1320-9030
Ehmsen, Jeffrey T.
Fields, Emily https://orcid.org/0000-0001-7352-5260
Kohli, Sajeev
Radtke, Stefan https://orcid.org/0000-0002-2842-4820
Swing, Kyle
Pande, Dnyanada https://orcid.org/0000-0001-9343-0584
Enstrom, Mark R. https://orcid.org/0000-0003-2635-3771
Laszlo, George S.
Mayuranathan, Thiyagaraj
Ali, Abdullah Mahmood https://orcid.org/0000-0002-4007-6769
Weiss, Mitchell J. https://orcid.org/0000-0002-6734-4858
Yen, Jonathan S. https://orcid.org/0000-0002-9432-9450
Newby, Gregory A. https://orcid.org/0000-0001-7869-2615
Walter, Roland B. https://orcid.org/0000-0002-9268-3341
Liu, David R. https://orcid.org/0000-0002-9943-7557
Mukherjee, Siddhartha https://orcid.org/0000-0001-8251-7334
Kiem, Hans-Peter https://orcid.org/0000-0001-5949-4947
- License Information
-
More Information
Article History
Received: 27 February 2023
Accepted: 2 May 2025
First Online: 27 May 2025
Competing interests
: This study was funded by a grant from Vor Biopharma and 1R21CA256461 at Columbia University and by grants from NIH/NHLBI (R01 HL136135_2) and NIH/NCI (R01 CA266556) at Fred Hutchinson Cancer Center. Columbia University has licensed technology that is the subject of this study to Vor Biopharma. F.B., A.M.A., and S.M. are coinventors on issued and pending patent applications licensed to Vor Biopharma. S.M. has equity ownership and is on the Scientific Advisory Board of Vor Biopharma. R.B.W. received laboratory research grants and/or clinical trial support from Aptevo, Celgene/Bristol Myers Squibb, ImmunoGen/AbbVie, Janssen, Jazz, Kite, Kura, Pfizer, and Vor Biopharma, and has been a consultant to Wugen. HPK is or was a consultant to and has or had ownership interests with Rocket Pharmaceuticals, Homology Medicines, Vor Biopharma and Ensoma Inc. H-P.K. has also been a consultant to CSL Behring and Magenta Therapeutics. D.R.L. is a consultant for Prime Medicine, Beam Therapeutics, Pairwise Plants, and Chroma Medicine, and Nvelop Therapeutics, companies that use or deliver genome editing or genome engineering agents and owns equity in these companies. The remaining authors declare no competing interests.
